Wright Medical Group N.V. (WMGI - Free Report) continues to benefit from strong international presence, solid prospects in the global orthopedic space and improved product launches. However, adverse forex is a persistent concern.
The stock currently carries a Zacks Rank #3 (Hold).
Shares of Wright Medical have lost 25.60%, wider than the industry’s decline of 7.7% in a year’s time. Meanwhile, the S&P 500 Index has risen 1.4%.
What’s Deterring the Stock?
Forex continues to remain a concern as the company generates a substantial portion of its total revenues from international operations. This, in turn, can be adversely affected by fluctuations in foreign currency exchange rates.
In fact, for 2019, Wright Medical anticipates a 1% headwind related to foreign currency.
What’s Favoring the Stock?
Wright Medical has been gaining from international expansion for quite some time now. In fact, the company’s international net sales are anticipated to improve significantly on the back of a steady performance in Biologics.
Further, the company has been reaping benefits from improving trends in the global orthopedic space.
Moreover, the company has a significant presence in the key emerging markets like Asia, which further boosts prospects.
Additionally, the company’s diversified product portfolio has been bolstering its overall performance over a considerable period of time. Notably, the company is likely to gain from the upcoming launch of REVIVE revision shoulder system.
Product launches, which include internally developed products and those from acquisitions, have been driving the company’s top line and we expect this trend to continue in the future.
Interestingly, the Cartiva buyout is expected to open up market opportunities worth $400 million for Wright Medical. For the remainder of 2019, Cartiva sales are projected at $13 million. The same for the third and fourth quarters of 2019 is estimated at $5.5 million and $7.5 million, respectively.
Which Way Are Estimates Trending?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $927.5 million, indicating an improvement of 10.9% from the year-ago reported figure. The same for earnings stands at 16 cents per share.
Some better-ranked stocks from the broader medical space are Baxter International Inc. (BAX - Free Report) , Amedisys, Inc. (AMED - Free Report) and CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter has a long-term earnings growth rate of 12.8%.
Amedisys has a long-term earnings growth rate of 16.3%.
CONMED has a long-term earnings growth rate 14.9%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>